Search Within

Chung-Han Lee

Formats
  1. Meeting Abstract (79)
  2. Journal Article (63)
  3. Review (9)
  4. Research Letter (3)
  5. Book Section (2)
  6. Guidelines (1)
Groups
  1. Department of Medicine (157)
  2. Genitourinary Oncology Service (157)
  3. Solid Tumor Oncology Division (157)
  4. Hematology-Oncology Fellows (87)
  5. Weinberg Fellows (86)
  6. Department of Pathology and Laboratory Medicine (59)

More Groups

People
  1. Robert Motzer (109)
  2. Martin Voss (75)
  3. Darren Feldman (55)
  4. Maria Carlo (55)
  5. Abraham Hakimi (42)
  6. Ritesh Kotecha (42)

More People

Years
  1. 2025 (4)
  2. 2024 (9)
  3. 2023 (19)
  4. 2022 (23)
  5. 2021 (20)
  6. 2020 (20)

More Years

Publications
  1. Journal of Clinical Oncology (63)
  2. Annals of Oncology (9)
  3. Clinical Cancer Research (6)
  4. Clinical Genitourinary Cancer (6)
  5. European Urology (5)
  6. European Urology Oncology (4)

More Publications

Publishers
  1. American Society of Clinical Oncology (66)
  2. Oxford University Press (13)
  3. Elsevier Inc. (11)
  4. Nature Publishing Group (11)
  5. American Association for Cancer Research (9)
  6. Elsevier Science, Inc. (7)

More Publishers

Results (157)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Association of body mass index (BMI) with clinical outcomes in 203 metastatic clear cell renal cell carcinoma (ccRCC) patients (pts) treated with immuno-oncology (IO) agents
    Meeting Abstract

    Ged, Y.; Lee, C. H.; Sanchez, A.; Duzgol, C.; Chaim, J.; Carlo, M. I.; Foster, A.; Akin, O.; Feldman, D. R.; Hakimi, A. A.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Systemic therapy for advanced clear cell renal cell carcinoma (ccRCC) after progression on immune-oncology plus VEGF targeted therapy combinations (IO-VEGF)
    Meeting Abstract

    Ged, Y.; Gupta, R.; Duzgol, C.; Shapnik, N.; Redzematovic, A.; Kotecha, R.; Voss, M. H.; Feldman, D. R.; Akin, O.; Patil, S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A pilot safety study of gemcitabine and cisplatin (GC) with atezolizumab (A) as first-line therapy in patients (pts) with metastatic urothelial cancer (mUC)
    Meeting Abstract

    Funt, S. A.; Jatwani, K.; Makris, M.; Regazzi, A. M.; Lee, C. H.; Teo, M. Y.; McHugh, D. J.; McCoy, A. S.; Hettich, G.; Wong, P.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Invasive urothelial cancer (iUC) with FGFR3 hotspot mutation/fusion (FGFR3+): A molecularly and clinically distinctive entity?
    Meeting Abstract

    Mota, J. M. S. C.; Teo, M. Y.; Li, H.; Balar, A. V.; Milowsky, M. I.; Funt, S. A.; Lee, C. H.; Regazzi, A. M.; Berger, M. F.; Solit, D. B.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Genomic biomarkers of response to nivolumab/ipilimumab (nivo/ipi) and nivolumab (nivo) monotherapy in 108 patients with advanced renal cell carcinoma
    Meeting Abstract

    Lee, C. H.; Di Natale, R. G.; Chowell, D.; Makarov, V.; Redzematovic, A.; Murray, S. J.; Carlo, M. I.; Voss, M. H.; Feldman, D. R.; Motzer, R. J.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Alterations in DNA damage repair (DDR) genes and outcomes to systemic therapy in 225 immune-oncology (10) versus tyrosine kinase inhibitor (TKI) treated metastatic clear cell renal cell carcinoma (mccRCC) patients (pts)
    Meeting Abstract

    Ged, Y.; Chaim, J.; Knezevic, A.; Carlo, M. I.; Foster, A.; Feldman, D. R.; Teo, M. Y.; Riaz, N.; Lee, C. H.; Patil, S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • The impact of PBRM1 mutations on overall survival in greater than 2,100 patients treated with immune checkpoint blockade (ICB)
    Meeting Abstract

    Hakimi, A. A.; Ged, Y.; Flynn, J.; Hoen, D. R.; Di Natale, R. G.; Blum, K. A.; Makarov, V.; Kuo, F.; Carlo, M. I.; Lee, C. H.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Muscle invasive bladder cancer (MIBC) demonstrates neoadjuvant cisplatin-based chemotherapy (NAC) related changes in molecular subtype and immune infiltration
    Meeting Abstract

    Funt, S. A.; Solovyov, A.; Faltas, B. M.; Iyer, G.; Boyd, M. E.; Cipolla, C. K.; Regazzi, A. M.; Teo, M. Y.; Lee, C. H.; Al-Ahmadie, H.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • The current role for adjuvant and neoadjuvant therapy in renal cell cancer
    Review

    Gleeson, J. P.; Motzer, R. J.; Lee, C. H.
    Current Opinion in Urology (2019)

    Fulltext@MSK | Save
  • Mucinous tubular and spindle-cell carcinoma of the kidney: Clinical features, genomic profiles, and treatment outcomes
    Journal Article

    Ged, Y.; Chen, Y. B.; Knezevic, A.; Donoghue, M. T. A.; Carlo, M. I.; Lee, C. H.; Feldman, D. R.; Patil, S.; Hakimi, A. A.; Russo, P.; more...
    Clinical Genitourinary Cancer (2019)

    Fulltext@MSK | Save